1. Home
  2. SRPT vs FMS Comparison

SRPT vs FMS Comparison

Compare SRPT & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • FMS
  • Stock Information
  • Founded
  • SRPT 1980
  • FMS 1996
  • Country
  • SRPT United States
  • FMS Germany
  • Employees
  • SRPT N/A
  • FMS N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • FMS Misc Health and Biotechnology Services
  • Sector
  • SRPT Health Care
  • FMS Health Care
  • Exchange
  • SRPT Nasdaq
  • FMS Nasdaq
  • Market Cap
  • SRPT 12.2B
  • FMS 12.3B
  • IPO Year
  • SRPT 1997
  • FMS 1996
  • Fundamental
  • Price
  • SRPT $104.54
  • FMS $22.18
  • Analyst Decision
  • SRPT Strong Buy
  • FMS Hold
  • Analyst Count
  • SRPT 21
  • FMS 2
  • Target Price
  • SRPT $182.00
  • FMS $23.00
  • AVG Volume (30 Days)
  • SRPT 1.0M
  • FMS 316.9K
  • Earning Date
  • SRPT 11-06-2024
  • FMS 11-05-2024
  • Dividend Yield
  • SRPT N/A
  • FMS 2.86%
  • EPS Growth
  • SRPT N/A
  • FMS 46.47
  • EPS
  • SRPT 1.22
  • FMS 2.50
  • Revenue
  • SRPT $1,640,348,000.00
  • FMS $21,457,738,113.00
  • Revenue This Year
  • SRPT $45.98
  • FMS $0.24
  • Revenue Next Year
  • SRPT $78.13
  • FMS $3.41
  • P/E Ratio
  • SRPT $85.70
  • FMS $17.59
  • Revenue Growth
  • SRPT 48.45
  • FMS N/A
  • 52 Week Low
  • SRPT $78.67
  • FMS $17.93
  • 52 Week High
  • SRPT $173.25
  • FMS $22.76
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 23.65
  • FMS 66.52
  • Support Level
  • SRPT $116.32
  • FMS $21.06
  • Resistance Level
  • SRPT $122.63
  • FMS $21.48
  • Average True Range (ATR)
  • SRPT 4.97
  • FMS 0.31
  • MACD
  • SRPT -2.19
  • FMS 0.14
  • Stochastic Oscillator
  • SRPT 6.47
  • FMS 99.39

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Share on Social Networks: